Animal models are established, important tools for preclinical safety and efficacy testing. Companies are advancing more “humanized” models to better reflect human responses, while at the same time ...
Drug development remains one of the most resource-intensive and failure-prone endeavors in modern science. Despite significant advances in artificial intelligence and computational chemistry, the ...
Leptomeningeal disease (LMD) is a subtype of central nervous system metastatic disease that is associated with poor patient outcomes and limited treatment options. There is an unmet need to develop ...
Pancreatic cancer (PC) is one of the deadliest human malignancies worldwide, ranked as 7th leading cause of cancer-related deaths with a median patient survival of 6–8 months post-diagnosis 1,2. Due ...
The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s applications ...
TG-MVATM uses a scalable cell line manufacturing process intended to strengthen and diversify global mpox and smallpox vaccine supplyTG-MVATM ...
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in ...
The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and ...
Capivasertib and venetoclax combination shows efficacy in PTEN-wildtype and PTEN-deficient diffuse large B-cell lymphoma (DLBCL) models, inducing caspase and PARP cleavage and inhibiting tumor growth.
In the UK, there was a case where TGN1412, an immunotherapy under development, triggered a cytokine storm within hours of administration to humans, leading to multiple organ failure. Another example, ...
This article and associated images are based on a poster originally authored by Kieran Casey, Yuzhou Xu, Jichuan Zhang, Shuyue Wang, Yanfei Hu, Ye Tian, Min Lyu, Ziyu Chen, Ya Xu, Qikuan Chen and ...
A new study from RCSI University of Medicine and Health Sciences demonstrates a novel approach in anticancer vaccine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results